These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25947141)

  • 1. Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults.
    Varewijck AJ; Lamberts SW; van der Lely AJ; Neggers SJ; Hofland LJ; Janssen JA
    Eur J Endocrinol; 2015 Aug; 173(2):119-27. PubMed ID: 25947141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different cut-off limits of peak GH after GHRH-arginine stimulatory test, single IGF1 measurement, or their combination in identifying adult patients with GH deficiency.
    Bogazzi F; Manetti L; Lombardi M; Giovannetti C; Raffaelli V; Urbani C; Scattina I; Pepe P; Iannelli A; Martino E; Rossi G
    Eur J Endocrinol; 2011 May; 164(5):685-93. PubMed ID: 21307143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNPs within the GH-signaling pathway are associated with the early IGF1 response to GH replacement therapy in GHD adults.
    Glad CA; Barbosa EJ; Filipsson Nyström H; Carlsson LM; Nilsson S; Nilsson AG; Svensson PA; Johannsson G
    Eur J Endocrinol; 2014 Jan; 170(1):101-7. PubMed ID: 24114431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency.
    Zucchini S; Pirazzoli P; Baronio F; Gennari M; Bal MO; Balsamo A; Gualandi S; Cicognani A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4271-6. PubMed ID: 16912138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy.
    Barbosa EJ; Glad CA; Nilsson AG; Filipsson Nyström H; Götherström G; Svensson PA; Vinotti I; Bengtsson BÅ; Nilsson S; Boguszewski CL; Johannsson G
    Eur J Endocrinol; 2012 Sep; 167(3):353-62. PubMed ID: 22715478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of IGF1 estimation in adults with GH deficiency.
    Mukherjee A; Shalet SM
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S33-9. PubMed ID: 19684059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
    Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
    Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-I bioactivity better reflects growth hormone deficiency than total IGF-I.
    Varewijck AJ; Lamberts SW; Uitterlinden P; Hofland LJ; Janssen JA
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2248-54. PubMed ID: 21565786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    Feldt-Rasmussen U; Brabant G; Maiter D; Jonsson B; Toogood A; Koltowska-Haggstrom M; Rasmussen AK; Buchfelder M; Saller B; Biller BM
    Eur J Endocrinol; 2013 May; 168(5):733-43. PubMed ID: 23416951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children.
    Efthymiadou A; Kritikou D; Mantagos S; Chrysis D
    Eur J Endocrinol; 2016 Apr; 174(4):473-9. PubMed ID: 26764419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary IGF-I deficiency as a prognostic factor of growth hormone (GH) therapy effectiveness in children with isolated, non-acquired GH deficiency.
    Smyczyńska J; Stawerska R; Hilczer M; Lewiński A
    Exp Clin Endocrinol Diabetes; 2015 Apr; 123(4):209-14. PubMed ID: 25607339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and total IGFBP3 for the assessment of disorders of the GH/IGF1 axis in children with chronic kidney disease, GH deficiency, or short stature after SGA status at birth.
    Büscher AK; Büscher R; Pridzun L; Langkamp M; Wachendorfer N; Hoyer PF; Ranke MB; Hauffa BP
    Eur J Endocrinol; 2012 May; 166(5):923-31. PubMed ID: 22318747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal of a clinical response score and predictors of clinical response to 2 years of GH replacement therapy in adult GH deficiency.
    Schneider HJ; Buchfelder M; Wallaschofski H; Luger A; Johannsson G; Kann PH; Mattsson A
    Eur J Endocrinol; 2015 Dec; 173(6):843-51. PubMed ID: 26369579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults.
    Barbosa EJ; Koranyi J; Filipsson H; Bengtsson BA; Boguszewski CL; Johannsson G
    Eur J Endocrinol; 2010 May; 162(5):869-78. PubMed ID: 20145045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in serum GH cut-off values for pharmacological tests of GH secretion depend on the serum GH method. Clinical validation from the growth velocity score during the first year of treatment.
    Chaler EA; Rivarola MA; Guerci B; Ciaccio M; Costanzo M; Travaglino P; Maceiras M; Pagani S; Meazza C; Bozzola E; Barberi S; Bozzola M; Belgorosky A
    Horm Res; 2006; 66(5):231-5. PubMed ID: 16912509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on insulin sensitivity and body composition of combination therapy with GH and IGF1 in GH deficient adults with type 2 diabetes.
    Barner C; Petersson M; Edén Engström B; Höybye C
    Eur J Endocrinol; 2012 Nov; 167(5):697-703. PubMed ID: 22945298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
    Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
    J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency.
    Losa M; Scavini M; Gatti E; Rossini A; Madaschi S; Formenti I; Caumo A; Stidley CA; Lanzi R
    Thyroid; 2008 Dec; 18(12):1249-54. PubMed ID: 19012473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.